基蛋生物(603387.SH)擬對新加坡基蛋增資及新設立全資子公司香港基蛋
格隆匯6月6日丨基蛋生物(603387.SH)發佈公吿,根據公司戰略發展需要,經總經理辦公會審議,公司於2020年6月設立了全資子公司新加坡基蛋生物科技有限公司,註冊資本50萬新幣,公司持股100%,為了進一步增強該全資子公司的運營及抗風險能力,公司擬對該全資子公司進行增資,將投資額由設立時的200萬新幣提升至1,000萬美元,由公司自有資金進行投資,增資後註冊資本不變,公司持股比例仍為100%。
同時,根據公司發展戰略規劃,公司擬使用自有資金3,000萬美元於香港設立全資子公司香港基蛋,註冊資本500萬美元,公司持股比例為100%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.